Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
03 10 2022
03 10 2022
Historique:
received:
08
05
2022
revised:
29
06
2022
accepted:
11
07
2022
pubmed:
15
7
2022
medline:
5
10
2022
entrez:
14
7
2022
Statut:
ppublish
Résumé
We report efficacy and safety of 90Y-labeled FAPI-46 (90Y-FAPI-46-RLT) in patients with advanced sarcoma, pancreatic cancer, and other cancer entities. Up to four cycles of radioligand therapy (RLT) were offered to patients with (i) progressive metastatic malignancy, (ii) exhaustion of approved therapies, and (iii) high fibroblast activation protein (FAP) expression, defined as SUVmax ≥ 10 in more than 50% of tumor. Primary endpoint was RECIST response after RLT. Secondary endpoints included PET response (PERCIST), overall survival (OS), dosimetry, and safety of FAP-RLT. Among 119 screened patients, 21 (18%) were found eligible [n = 16/3/1/1 sarcoma/pancreatic cancer/prostate/gastric cancer; 38% Eastern Cooperative Oncology Group (ECOG) ≥ 2] and received 47 90Y-FAPI-46-RLT cycles; 16 of 21 (76%) patients underwent repeat RLT. By RECIST, disease control was confirmed in 8 of 21 patients [38%; 8/16 (50%) of evaluable patients). There was one partial response (PR) and seven stable diseases after RLT. Disease control was associated with prolonged OS (P = 0.013). PERCIST response was noted in 8 of 21 patients [38%; 8/15 (53%) of evaluable patients]. Dosimetry was acquired in 19 (90%) patients. Mean absorbed dose was 0.53 Gy/GBq in kidney, 0.04 Gy/GBq in bone marrow, and <0.14 Gy/GBq in liver and lung. Treatment-related grade 3 or 4 adverse events were observed in 8 (38%) patients with thrombocytopenia (n = 6) and anemia (n = 6) being most prevalent. 90Y-FAPI-46-RLT was safe and led to RECIST PR in one case as well as stable disease in about one third of patients with initially progressive sarcomas, pancreatic cancer, and other cancers. Discontinuation after the first cycle and a low rate of PR requires future improvement of FAP-RLT.
Identifiants
pubmed: 35833949
pii: 707013
doi: 10.1158/1078-0432.CCR-22-1432
pmc: PMC9527500
doi:
Substances chimiques
FAPI-46
0
Quinolines
0
Yttrium Radioisotopes
0
Yttrium-90
1K8M7UR6O1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4346-4353Informations de copyright
©2022 The Authors; Published by the American Association for Cancer Research.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Curr Oncol. 2020 Feb;27(Suppl 1):25-33
pubmed: 32174755
J Nucl Med. 2018 Sep;59(9):1415-1422
pubmed: 29626119
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9
pubmed: 2402505
J Nucl Med. 2017 Sep;58(9):1435-1441
pubmed: 28450554
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Lancet. 2021 Feb 27;397(10276):797-804
pubmed: 33581798
J Nucl Med. 2022 Mar;63(3):415-423
pubmed: 34168013
Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1238-50
pubmed: 20411259
EJNMMI Phys. 2020 Mar 4;7(1):14
pubmed: 32130554
CA Cancer J Clin. 2020 May;70(3):200-229
pubmed: 32275330
Clin Cancer Res. 2007 Mar 15;13(6):1736-41
pubmed: 17363526
J Nucl Med. 2013 Jan;54(1):33-41
pubmed: 23223392
Oncotarget. 2017 Jan 10;8(2):3581-3590
pubmed: 27683041
Q J Nucl Med Mol Imaging. 2021 Jul 26;:
pubmed: 34309334
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
J Nucl Med. 2022 Jan;63(1):89-95
pubmed: 33931468
Sarcoma. 2018 May 24;2018:5467057
pubmed: 29977133
J Nucl Med. 2021 Jun 1;62(6):779-786
pubmed: 33097632
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4089-4100
pubmed: 34050777
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):42-51
pubmed: 26318602
Thyroid. 2022 Jan;32(1):65-77
pubmed: 34641705
Clin Nucl Med. 2021 Nov 1;46(11):e523-e530
pubmed: 34269729
World J Clin Oncol. 2021 Sep 24;12(9):787-799
pubmed: 34631442
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Pancreas. 2008 Aug;37(2):154-8
pubmed: 18665076
J Nucl Med. 2019 Jun;60(6):801-805
pubmed: 30954939
N Engl J Med. 2014 Nov 27;371(22):2140-1
pubmed: 25427123
Histopathology. 2009 Oct;55(4):432-40
pubmed: 19817894
J Nucl Med. 2022 May;63(5):727-734
pubmed: 34385340
Radiother Oncol. 2021 Jul;160:192-201
pubmed: 33940087